

Brilliant Violet 650™ anti-mouse CD8a Antibody

Catalog# / Size	100741 / 125 µL 100742 / 50 µg
Clone	53-6.7
Regulatory Status	RUO
Other Names	T8, Lyt2, Ly-2
Isotype	Rat IgG2a, κ
Description	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse thymus or spleen
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.

[Learn more about Brilliant Violet™.](#)

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes³. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a⁺ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation^{1,3}, *in vivo* and *in vitro* cell depletion^{2,10,15}, inhibition of CD8 T cell proliferation³, blocking of cytotoxicity^{3,4}, immunohistochemical staining^{5,6} of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)^{29,30}. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays or *in vivo* studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)

1. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IHC, IP)
2. Hathcock KS. 1991. *Current Protocols in Immunology.* 3.4.1. (Deplete)
3. Takahashi K, *et al.* 1992. *P. Natl. Acad. Sci. USA* 89:5557. (Block, IP)
4. Ledbetter JA, *et al.* 1981. *J. Exp. Med.* 153:1503. (Block)
5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, *et al.* 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, *et al.* 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, *et al.* 2005. *Int. Immunol.* 17:1607. [PubMed](#)
11. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
12. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
13. Lee CH, *et al.* 2009. *Clin. Cancer Res.* [PubMed](#)
14. Geiben-Lynn R, *et al.* 2008. *Blood* 112:4585. (Deplete) [PubMed](#)
15. Kingeter LM, *et al.* 2008. *J. Immunol.* 181:6244. [PubMed](#)
16. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
17. Andrews DM, *et al.* 2008. *J. Virol.* 82:4931. [PubMed](#)
18. Britschqui MR, *et al.* 2008. *J. Immunol.* 181:7681. [PubMed](#)
19. Kenna TJ, *et al.* 2008. *Blood* 111:2091. [PubMed](#)
20. Jordan JM, *et al.* 2008. *Infect. Immun.* 76:3717. [PubMed](#)
21. Todd DJ, *et al.* 2009. *J. Exp. Med.* 206:2151. [PubMed](#)
22. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
23. Medyouf H, *et al.* 2010. *Blood* 115:1175. [PubMed](#)
24. Riedl P, *et al.* 2009. *J. Immunol.* 183:370. [PubMed](#)
25. Apte SH, *et al.* 2010. *J. Immunol.* 185:998. [PubMed](#)
26. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
27. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
28. Cui L, *et al.* 2015. *J Control Release.* 206:220. [PubMed](#)
29. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
30. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Flamar AL, *et al.* 2020. *Immunity.* 52(4):606-619.e6. [PubMed](#)
2. Schädlich IS, *et al.* 2022. *iScience.* 25:104470. [PubMed](#)
3. Wiesner DL, *et al.* 2020. *Cell Host Microbe.* 614:27. [PubMed](#)
4. Boyd DF, *et al.* 2020. *Nature.* 587:466. [PubMed](#)
5. Kloepper J, *et al.* 2016. *Proc Natl Acad Sci U S A.* 113: 4476-4481. [PubMed](#)
6. Arce Vargas F *et al.* 2018. *Cancer cell.* 33(4):649-663. [PubMed](#)
7. Schönberger K, *et al.* 2022. *Cell Stem Cell.* 29:131. [PubMed](#)
8. Suresh R, *et al.* 2020. *J Immunother Cancer.* 8: [PubMed](#)
9. Baptista AP *et al.* 2019. *Immunity.* 50(5):1188-1201. [PubMed](#)
10. Piepke M, *et al.* 2021. *J Neuroinflammation.* 18:265. [PubMed](#)
11. Sauter M, *et al.* 2022. *iScience.* 25:103677. [PubMed](#)
12. Coleby R, *et al.* 2021. *Clin Exp Rheumatol.* :39. [PubMed](#)
13. Abou-Hamad J, *et al.* 2022. *iScience.* 25:105524. [PubMed](#)
14. McLane LM, *et al.* 2021. *Cell Reports.* 35(6):109120. [PubMed](#)
15. Mier-Aguilar C, *et al.* 2016. *PLoS One.* 11:e0168155. [PubMed](#)
16. Kumar V, *et al.* 2022. *Front Cardiovasc Med.* 9:992653. [PubMed](#)
17. Su W, *et al.* 2020. *Cell Metabolism.* 32(6):996-1011.e7. [PubMed](#)
18. Molina-Sanchez P, *et al.* 2020. *Gastroenterology.* 2203:159. [PubMed](#)
19. Han Y *et al.* 2019. *Cell reports.* 27(3):835-846. [PubMed](#)
20. Kumar S, *et al.* 2021. *Cancer Discov.* 11:2050. [PubMed](#)
21. Linnerbauer M, *et al.* 2022. *Front Immunol.* 12:800128. [PubMed](#)
22. Marangoni F, *et al.* 2021. *Cell.* [PubMed](#)
23. Cousin N, *et al.* 2021. *Cancer Res.* 81:4133. [PubMed](#)
24. Doty DT, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
25. Gary EN, *et al.* 2021. *iScience.* 24(7):102699. [PubMed](#)
26. MacDonald A, *et al.* 2021. *Front Immunol.* 12:755995. [PubMed](#)
27. Lovisa S, *et al.* 2020. *Sci Signal.* 13:00. [PubMed](#)
28. Sidwell T, *et al.* 2020. *Nat Commun.* 0.6333333333. [PubMed](#)
29. McAndrews KM, *et al.* 2021. *Oncogene.* 40:4440. [PubMed](#)
30. Dokoshi T, *et al.* 2021. *J Clin Invest.* 131: [PubMed](#)
31. Espinosa JR, *et al.* 2018. *Front Immunol.* 9:1371. [PubMed](#)
32. Chen Z *et al.* 2019. *Immunity.* 51(5):840-855. [PubMed](#)
33. Wang Y, *et al.* 2021. *Cell Rep.* 35:108948. [PubMed](#)

34. Roberta Zappasodi *et al.* 2018. *Cancer cell*. 33(6):1017-1032 . [PubMed](#)
35. Carter TJ, *et al.* 2021. *Small*. 17:e2005241. [PubMed](#)
36. Walton ZE *et al.* 2018. *Cell*. 174(1):72-87 . [PubMed](#)
37. Zhou Z, *et al.* 2022. *Infect Immun*. 90:e0045321. [PubMed](#)
38. Port JR, *et al.* 2020. *J Virol*. 94:. [PubMed](#)
39. Chiang HY, *et al.* 2022. *Nat Commun*. 13:874. [PubMed](#)
40. Xi-Zhi J Guo *et al.* 2018. *Immunity*. 49(3):531-544 . [PubMed](#)
41. Di Mitri D, *et al.* 2019. *Cell Rep*. 28:2156. [PubMed](#)
42. Cabrera-Perez J, *et al.* 2016. *J Immunol*. 197: 1692 - 1698. [PubMed](#)
43. Herrera R, *et al.* 2015. *Infect Immun* . 83: 3771 - 3780.. [PubMed](#)
44. Cabrera-Perez C, *et al.* 2015. *J Immunol* . 194:1609-20. [PubMed](#)
45. Śledzińska A, *et al.* 2020. *Immunity*. 52(1):151-166.e6.. [PubMed](#)
46. Yeung F, *et al.* 2020. *Cell Host & Microbe*. 27(5):809-822. [PubMed](#)
47. Rosenbaum SR, *et al.* 2020. *Cell Rep*. 30:510. [PubMed](#)
48. Qadir AS, *et al.* 2021. *iScience*. 24:103348. [PubMed](#)
49. McAndrews KM, *et al.* 2021. *J Biol Chem*. 296:100523. [PubMed](#)
50. Ko HJ, *et al.* 2020. *Front Immunol*. 1897:11. [PubMed](#)
51. Laban H, *et al.* 2018. *J Cell Biol*. 217:1503. [PubMed](#)
52. Shi H, *et al.* 2020. *Immunity*. 51(6):1012-1027.e7.. [PubMed](#)
53. Cartwright ANR, *et al.* 2021. *Cancer Immunol Res*. 9:470. [PubMed](#)
54. Chen Z, *et al.* 2021. *Cell*. 184(5):1262-1280.e22. [PubMed](#)
55. Bagati A, *et al.* 2020. *Cancer Cell*. 39(1):54-67.e9. [PubMed](#)
56. Silva DA, *et al.* 2019. *Nature*. 565:186. [PubMed](#)
57. Sun Y, *et al.* 2020. *J Immunol*. 205:2649. [PubMed](#)
58. Smith KJ, *et al.* 2022. *PLoS Biol*. 20:e3001554. [PubMed](#)
59. Graham JB, *et al.* 2017. *Curr Protoc Mouse Biol*. 7:221. [PubMed](#)
60. Shi H *et al.* 2018. *Immunity*. 49(5):899-914 . [PubMed](#)
61. Alam IS, *et al.* 2020. *Cancer Res*. 80:4780. [PubMed](#)
62. Kong IY, *et al.* 2020. *Cell Rep*. 33:108290. [PubMed](#)
63. Goc J, *et al.* 2021. *Cell*. :. [PubMed](#)
64. Orr MT, *et al.* 2019. *NPJ Vaccines*. 4:1. [PubMed](#)
65. Henkle TR, *et al.* 2021. *Cancer Res*. 81:4560. [PubMed](#)
66. Deets KA, *et al.* 2021. *Elife*. 10:. [PubMed](#)
67. Tseng SH, *et al.* 2021. *J Biomed Sci*. 28:63. [PubMed](#)
68. Chang MH, *et al.* 2021. *Cell Rep*. 37:109902. [PubMed](#)

RRID AB_11124344 (BioLegend Cat. No. 100741)
 AB_2563056 (BioLegend Cat. No. 100742)

Antigen Details

Structure	Ig superfamily, CD8α chain, 34 kD
Distribution	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function	Co-receptor for TCR
Ligand/Receptor	MHC class I molecule
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press. 2. Zamoyska R. 1994. <i>Immunity</i> 1:243. 3. Ellmeier W, <i>et al.</i> 1999. <i>Annu. Rev. Immunol.</i> 17:523.
Gene ID	12525

Related Protocols


[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a, Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a,

GolnVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a

Product Data



C57BL/6 mouse splenocytes were stained with CD3 PE and CD8a (clone 53-6.7) Brilliant Violet 650™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587